메뉴 건너뛰기




Volumn 8, Issue , 2014, Pages 365-371

Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophiliac

Author keywords

Factor IX; Factor VIII; Long acting molecules

Indexed keywords

ALBUMIN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; FC RECEPTOR; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; MACROGOL; PLASMA PROTEIN; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9;

EID: 84897562467     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S47312     Document Type: Review
Times cited : (22)

References (36)
  • 1
    • 0035822038 scopus 로고    scopus 로고
    • The hemophilias - from royal genes to gene therapy
    • Mannucci PM, Tuddenham EG. The hemophilias - from royal genes to gene therapy. N Engl J Med. 2001;344(23):1773-1779.
    • (2001) N Engl J Med , vol.344 , Issue.23 , pp. 1773-1779
    • Mannucci, P.M.1    Tuddenham, E.G.2
  • 2
    • 34547757915 scopus 로고    scopus 로고
    • Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia
    • Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357(6):535-544.
    • (2007) N Engl J Med , vol.357 , Issue.6 , pp. 535-544
    • Manco-Johnson, M.J.1    Abshire, T.C.2    Shapiro, A.D.3
  • 3
    • 79953306825 scopus 로고    scopus 로고
    • A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)
    • ESPRIT Study Group
    • Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM; ESPRIT Study Group. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost. 2011;9(4):700-710.
    • (2011) J Thromb Haemost , vol.9 , Issue.4 , pp. 700-710
    • Gringeri, A.1    Lundin, B.2    von Mackensen, S.3    Mantovani, L.4    Mannucci, P.M.5
  • 4
    • 59849093369 scopus 로고    scopus 로고
    • rAHF-PFM Study Group. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A
    • Collins PW, Blanchette VS, Fischer K, et al; rAHF-PFM Study Group. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost. 2009;7(3):413-420.
    • (2009) J Thromb Haemost , vol.7 , Issue.3 , pp. 413-420
    • Collins, P.W.1    Blanchette, V.S.2    Fischer, K.3
  • 5
    • 74749088081 scopus 로고    scopus 로고
    • Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: Influences of variance in pharmacokinetics and treatment regimens
    • Collins PW, Björkman S, Fischer K, et al. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost. 2010;8(2):269-275.
    • (2010) J Thromb Haemost , vol.8 , Issue.2 , pp. 269-275
    • Collins, P.W.1    Björkman, S.2    Fischer, K.3
  • 6
    • 78649903536 scopus 로고    scopus 로고
    • Venous access in the management of hemophilia
    • Valentino LA, Kawji M, Grygotis M. Venous access in the management of hemophilia. Blood Rev. 2011;25(1):11-15.
    • (2011) Blood Rev , vol.25 , Issue.1 , pp. 11-15
    • Valentino, L.A.1    Kawji, M.2    Grygotis, M.3
  • 7
    • 84859197329 scopus 로고    scopus 로고
    • Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients
    • Powell JS, Josephson NC, Quon D, et al. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood. 2012;119(13):3031-3037.
    • (2012) Blood , vol.119 , Issue.13 , pp. 3031-3037
    • Powell, J.S.1    Josephson, N.C.2    Quon, D.3
  • 8
    • 84862908041 scopus 로고    scopus 로고
    • Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients
    • Shapiro AD, Ragni MV, Valentino LA, et al. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood. 2012;119(3):666-672.
    • (2012) Blood , vol.119 , Issue.3 , pp. 666-672
    • Shapiro, A.D.1    Ragni, M.V.2    Valentino, L.A.3
  • 9
    • 84893123337 scopus 로고    scopus 로고
    • Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A
    • Mahlangu J, Powell JS, Ragni MV, et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2014;123:317-325.
    • (2014) Blood , vol.123 , pp. 317-325
    • Mahlangu, J.1    Powell, J.S.2    Ragni, M.V.3
  • 10
    • 84889769562 scopus 로고    scopus 로고
    • Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B
    • Powell JS, Pasi KJ, Ragni MV, et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med. 2013;369:2313-2323.
    • (2013) N Engl J Med , vol.369 , pp. 2313-2323
    • Powell, J.S.1    Pasi, K.J.2    Ragni, M.V.3
  • 11
    • 0029900294 scopus 로고    scopus 로고
    • Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group
    • Fisher CJ, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med. 1996;334(26):1697-1702.
    • (1996) N Engl J Med , vol.334 , Issue.26 , pp. 1697-1702
    • Fisher, C.J.1    Agosti, J.M.2    Opal, S.M.3
  • 12
    • 0035954670 scopus 로고    scopus 로고
    • Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes
    • Alefacept Clinical Study Group
    • Ellis CN, Krueger GG; Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med. 2001;345(4):248-255.
    • (2001) N Engl J Med , vol.345 , Issue.4 , pp. 248-255
    • Ellis, C.N.1    Krueger, G.G.2
  • 13
    • 24944498854 scopus 로고    scopus 로고
    • Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition
    • Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353(11):1114-1123.
    • (2005) N Engl J Med , vol.353 , Issue.11 , pp. 1114-1123
    • Genovese, M.C.1    Becker, J.C.2    Schiff, M.3
  • 14
    • 0030880901 scopus 로고    scopus 로고
    • Expression of the neonatal Fc receptor, FcRn, on human intestinal epithelial cells
    • Israel EJ, Taylor S, Wu Z, et al. Expression of the neonatal Fc receptor, FcRn, on human intestinal epithelial cells. Immunology. 1997;92(1): 69-74.
    • (1997) Immunology , vol.92 , Issue.1 , pp. 69-74
    • Israel, E.J.1    Taylor, S.2    Wu, Z.3
  • 15
    • 0037025895 scopus 로고    scopus 로고
    • Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: Functional expression of FcRn in the mammalian lung
    • Spiekermann GM, Finn PW, Ward ES, et al. Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung. J Exp Med. 2002;196(3): 303-310.
    • (2002) J Exp Med , vol.196 , Issue.3 , pp. 303-310
    • Spiekermann, G.M.1    Finn, P.W.2    Ward, E.S.3
  • 16
    • 0034023794 scopus 로고    scopus 로고
    • Characterization and localization of the neonatal Fc receptor in adult human kidney
    • Haymann JP, Levraud JP, Bouet S, et al. Characterization and localization of the neonatal Fc receptor in adult human kidney. J Am Soc Nephrol. 2000;11(4):632-639.
    • (2000) J Am Soc Nephrol , vol.11 , Issue.4 , pp. 632-639
    • Haymann, J.P.1    Levraud, J.P.2    Bouet, S.3
  • 17
    • 0035113258 scopus 로고    scopus 로고
    • Expression of functionally active FcRn and the differentiated bidirectional transport of IgG in human placental endothelial cells
    • Antohe F, Rǎdulescu L, Gafencu A, Gheţie V, Simionescu M. Expression of functionally active FcRn and the differentiated bidirectional transport of IgG in human placental endothelial cells. Hum Immunol. 2001;62(2):93-105.
    • (2001) Hum Immunol , vol.62 , Issue.2 , pp. 93-105
    • Antohe, F.1    Rǎdulescu, L.2    Gafencu, A.3    Gheţie, V.4    Simionescu, M.5
  • 18
    • 0037325779 scopus 로고    scopus 로고
    • Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans
    • Ward ES, Zhou J, Ghetie V, Ober RJ. Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans. Int Immunol. 2003;15(2):187-195.
    • (2003) Int Immunol , vol.15 , Issue.2 , pp. 187-195
    • Ward, E.S.1    Zhou, J.2    Ghetie, V.3    Ober, R.J.4
  • 19
    • 0842343448 scopus 로고    scopus 로고
    • Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn
    • Ober RJ, Martinez C, Vaccaro C, Zhou J, Ward ES. Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn. J Immunol. 2004;172(4):2021-2029.
    • (2004) J Immunol , vol.172 , Issue.4 , pp. 2021-2029
    • Ober, R.J.1    Martinez, C.2    Vaccaro, C.3    Zhou, J.4    Ward, E.S.5
  • 20
    • 11844250025 scopus 로고    scopus 로고
    • A passionate kiss, then run: Exocytosis and recycling of IgG by FcRn
    • Lencer WI, Blumberg RS. A passionate kiss, then run: exocytosis and recycling of IgG by FcRn. Trends Cell Biol. 2005;15(1):5-9.
    • (2005) Trends Cell Biol , vol.15 , Issue.1 , pp. 5-9
    • Lencer, W.I.1    Blumberg, R.S.2
  • 21
    • 0020541752 scopus 로고
    • Intracellular distribution and degradation of immunoglobulin G and immunoglobulin G fragments injected into HeLa cells
    • McGarry T, Hough R, Rogers S, Rechsteiner M. Intracellular distribution and degradation of immunoglobulin G and immunoglobulin G fragments injected into HeLa cells. J Cell Biol. 1983;96(2):338-346.
    • (1983) J Cell Biol , vol.96 , Issue.2 , pp. 338-346
    • McGarry, T.1    Hough, R.2    Rogers, S.3    Rechsteiner, M.4
  • 22
    • 0026601671 scopus 로고
    • A study of macromolecular diffusion through native porcine mucus
    • Desai MA, Mutlu M, Vadgama P. A study of macromolecular diffusion through native porcine mucus. Experientia. 1992;48(1):22-26.
    • (1992) Experientia , vol.48 , Issue.1 , pp. 22-26
    • Desai, M.A.1    Mutlu, M.2    Vadgama, P.3
  • 23
    • 3042795848 scopus 로고    scopus 로고
    • Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway
    • Bitonti AJ, Dumont JA, Low SC, et al. Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc Natl Acad Sci U S A. 2004;101(26): 9763-9768.
    • (2004) Proc Natl Acad Sci U S A , vol.101 , Issue.26 , pp. 9763-9768
    • Bitonti, A.J.1    Dumont, J.A.2    Low, S.C.3
  • 24
    • 77950391547 scopus 로고    scopus 로고
    • Prolonged activity of factor IX as a monomeric Fc fusion protein
    • Peters RT, Low SC, Kamphaus GD, et al. Prolonged activity of factor IX as a monomeric Fc fusion protein. Blood. 2010;115(10):2057-2064.
    • (2010) Blood , vol.115 , Issue.10 , pp. 2057-2064
    • Peters, R.T.1    Low, S.C.2    Kamphaus, G.D.3
  • 25
    • 0033012077 scopus 로고    scopus 로고
    • Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis
    • discussion 1-2
    • Goldenberg MM. Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. Clin Ther. 1999;21(1):75-87.discussion 1-2.
    • (1999) Clin Ther , vol.21 , Issue.1 , pp. 75-87
    • Goldenberg, M.M.1
  • 26
    • 84859192874 scopus 로고    scopus 로고
    • Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs
    • Dumont JA, Liu T, Low SC, et al. Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs. Blood. 2012;119(13):3024-3030.
    • (2012) Blood , vol.119 , Issue.13 , pp. 3024-3030
    • Dumont, J.A.1    Liu, T.2    Low, S.C.3
  • 27
    • 84873043409 scopus 로고    scopus 로고
    • Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein
    • Peters RT, Toby G, Lu Q, et al. Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein. J Thromb Haemost. 2013;11(1):132-141.
    • (2013) J Thromb Haemost , vol.11 , Issue.1 , pp. 132-141
    • Peters, R.T.1    Toby, G.2    Lu, Q.3
  • 28
    • 84861642572 scopus 로고    scopus 로고
    • Human cells: New platform for recombinant therapeutic protein production
    • Swiech K, Picanço-Castro V, Covas DT. Human cells: new platform for recombinant therapeutic protein production. Protein Expr Purif. 2012;84(1):147-153.
    • (2012) Protein Expr Purif , vol.84 , Issue.1 , pp. 147-153
    • Swiech, K.1    Picanço-Castro, V.2    Covas, D.T.3
  • 29
    • 84860912187 scopus 로고    scopus 로고
    • Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation
    • Ghaderi D, Zhang M, Hurtado-Ziola N, Varki A. Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation. Biotechnol Genet Eng Rev. 2012;28: 147-175.
    • (2012) Biotechnol Genet Eng Rev , vol.28 , pp. 147-175
    • Ghaderi, D.1    Zhang, M.2    Hurtado-Ziola, N.3    Varki, A.4
  • 31
    • 0035895058 scopus 로고    scopus 로고
    • Recombinant Factor IX Study Group. Human recombinant factor IX: Safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates
    • Roth DA, Kessler CM, Pasi KJ, Rup B, Courter SG, Tubridy KL; Recombinant Factor IX Study Group. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood. 2001;98(13): 3600-3606.
    • (2001) Blood , vol.98 , Issue.13 , pp. 3600-3606
    • Roth, D.A.1    Kessler, C.M.2    Pasi, K.J.3    Rup, B.4    Courter, S.G.5    Tubridy, K.L.6
  • 32
    • 84897488040 scopus 로고    scopus 로고
    • Biogen Idec. Study of Recombinant Coagulation Factor VIII Fc Fusion Protein, BIIB 031, in Pediatric PTP Subjects With Hemophilia A. Updated December 12, 2013. Available from, NLM identifier: NCT01458106. Accessed February 17, 2014
    • Biogen Idec. Study of Recombinant Coagulation Factor VIII Fc Fusion Protein, BIIB 031, in Pediatric PTP Subjects With Hemophilia A. Updated December 12, 2013. Available from: http://clinicaltrials.gov/show/NCT01458106. NLM identifier: NCT01458106. Accessed February 17, 2014.
  • 33
    • 84897551652 scopus 로고    scopus 로고
    • ClinicalTrials.gov. Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor VIII Fusion Protein (rFVIIIFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia A. Last updated September 12, 2013. Available from
    • ClinicalTrials.gov. Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor VIII Fusion Protein (rFVIIIFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia A. Last updated September 12, 2013. Available from: http://clinicaltrials.gov/show/NCT01454739.
  • 34
    • 84897488823 scopus 로고    scopus 로고
    • ClinicalTrials.gov. Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB 029, in Pediatric PTP Subjects With Hemophilia B. Updated September 12, 2013. Available from
    • ClinicalTrials.gov. Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB 029, in Pediatric PTP Subjects With Hemophilia B. Updated September 12, 2013. Available from: http://clinicaltrials.gov/show/NCT01440946.
  • 35
    • 84897530973 scopus 로고    scopus 로고
    • ClinicalTrials.gov. Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor IX Fusion Protein (rFIXFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia B (B-YOND). Last updated September 12, 2013. Available from
    • ClinicalTrials.gov. Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor IX Fusion Protein (rFIXFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia B (B-YOND). Last updated September 12, 2013. Available from: http://clinicaltrials.gov/show/NCT01425723.
  • 36
    • 84866594053 scopus 로고    scopus 로고
    • Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients
    • Santagostino E, Negrier C, Klamroth R, et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood. 2012;120(12):2405-2411.
    • (2012) Blood , vol.120 , Issue.12 , pp. 2405-2411
    • Santagostino, E.1    Negrier, C.2    Klamroth, R.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.